LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Medtronic PLC

Closed

SectorHealthcare

87.41 0.59

Overview

Share price change

24h

Current

Min

86.78

Max

87.43

Key metrics

By Trading Economics

Income

16M

1.3B

Sales

-111M

8.3B

P/E

Sector Avg

23.197

51.198

EPS

1.62

Dividend yield

3.39

Profit margin

15.605

Employees

95,000

EBITDA

-42M

2.4B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+12.3% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.39%

2.40%

Next Earnings

19 Aug 2025

Next Dividend date

11 Jul 2025

Next Ex Dividend date

27 Jun 2025

Market Stats

By TradingEconomics

Market Cap

-13B

107B

Previous open

86.82

Previous close

87.41

News Sentiment

By Acuity

27%

73%

71 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Medtronic PLC Chart

Past performance is not a reliable indicator of future results.

Related News

21 May 2025, 11:38 UTC

Earnings
Acquisitions, Mergers, Takeovers

Medtronic Boosts Dividend, Plans to Separate Diabetes Business and Targets Revenue Growth for Year

18 Feb 2025, 12:24 UTC

Earnings

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

21 May 2025, 17:23 UTC

Top News
Acquisitions, Mergers, Takeovers

Medtronic to Separate Diabetes Business as Stand-Alone Company -- 2nd Update

21 May 2025, 11:39 UTC

Top News
Acquisitions, Mergers, Takeovers

Medtronic to Separate Diabetes Business as Stand-Alone Company -- Update

21 May 2025, 10:52 UTC

Earnings

Medtronic Sees FY26 Adjusted EPS Up About 4% Excluding Potential Impacts From Increased Tariffs >MDT

21 May 2025, 10:51 UTC

Earnings

Medtronic Sees FY26 Adj EPS $5.50-Adj EPS $5.60, Including Potential Tariff Impact >MDT

21 May 2025, 10:50 UTC

Earnings

Medtronic Sees FY26 Reported Revenue Up 4.8%-5.1% if Recent Forex Rates Hold >MDT

21 May 2025, 10:49 UTC

Earnings

Medtronic Sees FY26 Organic Revenue Growth Up About 5% >MDT

21 May 2025, 10:49 UTC

Earnings

Medtronic Names Michael Carter Sr VP, President of Cranial, Spinal Technologies >MDT

21 May 2025, 10:48 UTC

Earnings

Medtronic Names Skip Kiil Exec VP, President of Cardiovascular Portfolio >MDT

21 May 2025, 10:48 UTC

Earnings

Medtronic: Sean Salmon, Exec VP and President of, Cardiovascular Portfolio Leaving >MDT

21 May 2025, 10:47 UTC

Earnings

Medtronic Raises Quarterly Dividend to 71c From 70c >MDT

21 May 2025, 10:45 UTC

Acquisitions, Mergers, Takeovers

Medtronic: Preferred Path of Initial Public Offering, Subsequent Split-Off >MDT

21 May 2025, 10:45 UTC

Earnings

Medtronic Reports Strong Finish To Its Fiscal Year With Its Fourth Quarter Financial Results; Announces Dividend Increase >MDT

21 May 2025, 10:45 UTC

Earnings

Medtronic 4Q Net $1.06B >MDT

21 May 2025, 10:45 UTC

Earnings

Medtronic 4Q Medical Surgical Portfolio Rev $2.21B >MDT

21 May 2025, 10:45 UTC

Earnings

Medtronic 4Q Neuroscience Portfolio Rev $2.62B >MDT

21 May 2025, 10:45 UTC

Earnings

Medtronic 4Q Diabetes Rev $728M >MDT

21 May 2025, 10:45 UTC

Earnings

Medtronic 4Q Organic Revenue Up 5.4% >MDT

21 May 2025, 10:45 UTC

Earnings

Medtronic 4Q Adj EPS $1.62 >MDT

21 May 2025, 10:45 UTC

Earnings

Medtronic 4Q EPS 82c >MDT

21 May 2025, 10:45 UTC

Earnings

Medtronic 4Q Cardiovascular Portfolio Rev $3.34B >MDT

21 May 2025, 10:45 UTC

Earnings

Medtronic 4Q Sales $8.93B >MDT

21 May 2025, 09:00 UTC

Top News
Acquisitions, Mergers, Takeovers

Medtronic to Separate Diabetes Business as Stand-Alone Company -- WSJ

21 May 2025, 09:00 UTC

Acquisitions, Mergers, Takeovers

Medtronic to Separate Diabetes Business, Sources Say -- WSJ

21 May 2025, 09:00 UTC

Acquisitions, Mergers, Takeovers

Medtronic's Separation of Diabetes Business to Finish Within 18 Months, Sources Say -- WSJ

21 May 2025, 09:00 UTC

Acquisitions, Mergers, Takeovers

Medtronic Diabetes Business Sales Totaled Nearly $2.5B in 2024 -- WSJ

27 Feb 2025, 10:30 UTC

Top News

Squeezed by Strong Dollar, Companies Try to Neutralize Currency Swings -- WSJ

18 Feb 2025, 11:47 UTC

Earnings

Medtronic: Will Accelerate Top-, Bottom-Line Growth in 4Q >MDT

18 Feb 2025, 11:46 UTC

Earnings

Medtronic Still Sees FY25 Organic Revenue Growth 4.75%-5% >MDT

Peer Comparison

Price change

Medtronic PLC Forecast

Price Target

By TipRanks

12.3% upside

12 Months Forecast

Average 96.13 USD  12.3%

High 109 USD

Low 87 USD

Based on 20 Wall Street analysts offering 12 month price targets forMedtronic PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

20 ratings

11

Buy

9

Hold

0

Sell

Technical Score

By Trading Central

83.26 / 84.875Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

71 / 380 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.